Atenolol

Atenolol is a cardioselective beta blocker, meaning it preferentially blocks the beta-1 subtype of adrenergic receptor found chiefly in the heart, without significant intrinsic sympathomimetic activity. ^[1] By occupying these receptors it blunts the effect of adrenaline and related stress hormones on the heart.

It is prescribed for hypertension, angina (chest pain from reduced blood flow to the heart), and some cardiac arrhythmias, and it has been used to protect the heart after a myocardial infarction. ^[1] Because it slows heart rate and steadies rhythm, it is also used at times to control symptoms of an overactive thyroid and to blunt the physical symptoms of anxiety.

Atenolol was developed by the British company Imperial Chemical Industries and introduced in the 1970s as a more heart-selective alternative to earlier agents such as propranolol. ^[2] A notable pharmacological feature is that it is hydrophilic, or water-loving, and does not readily cross the blood-brain barrier, so it tends to produce fewer central effects such as vivid dreams or mood changes than fat-soluble beta blockers. ^[3]

Once a mainstay of blood-pressure treatment and a common comparator in clinical trials, atenolol's position has since been reassessed. Reviews found that, as a first-line treatment for uncomplicated hypertension, atenolol lowered blood pressure but did not reduce heart attacks, strokes, or deaths as effectively as some other drug classes, particularly in older patients. ^[1][2] As a result, several national guidelines downgraded beta blockers like atenolol from first-line status for hypertension in the mid-2000s. ^[1]

Atenolol remains a widely prescribed, inexpensive generic medicine and is included on the World Health Organization's List of Essential Medicines. It is a prescription-only drug taken by mouth as tablets, sometimes combined with a diuretic. It should not be stopped abruptly, since sudden withdrawal can worsen angina or blood pressure.

Atenolol is prescription only. Common effects are fatigue, cold hands and feet, a slow heart rate, dizziness and sometimes erectile problems or low mood. It can blunt the warning signs of low blood sugar in people using insulin. It should not be stopped abruptly because of rebound chest pain or racing heart, and it is used cautiously in asthma, very slow heart rates and certain types of heart block. Combining it with heart slowing calcium blockers such as verapamil or diltiazem can push the heart rate and conduction too low.

Atenolol combined with non-dihydropyridine calcium channel blockers such as verapamil or diltiazem can produce additive effects on atrioventricular (AV) conduction and heart rate. A comparative study in 30 patients with chronic atrial fibrillation showed that beta-blockers (including atenolol) increased latent AV conduction manifesting as increased interval variability (Rrmax/Rrmin ratio 0.4 higher in the beta-blocker group versus calcium antagonist groups), whereas verapamil and diltiazem did not show this effect and produced a more optimal rhythm pattern ^[4]. Combined use requires ECG monitoring for signs of AV block, and dosage adjustments may be necessary to avoid excessive bradycardia or conduction abnormalities.

Checking a whole stack? Run it through interactions + stacks.

Atenolol was developed in the 1970s by Imperial Chemical Industries, the British company whose pharmaceutical division had earlier produced the pioneering beta blocker propranolol. Chemists sought a cardioselective agent that would act preferentially on the heart's beta-1 receptors while being water-soluble enough to limit passage into the brain. Marketed as Tenormin, it became one of the most widely prescribed beta blockers of its era, used for high blood pressure, angina, arrhythmias, and after heart attacks. In later decades, analyses questioning its effect on hard outcomes in uncomplicated hypertension led many guidelines to move it away from first-line status for that indication.

Atenolol built a solid reputation as a dependable, once-daily beta blocker, and its water-soluble design is often cited for producing fewer central nervous system side effects such as vivid dreams or fatigue than more fat-soluble agents. It remains useful and widely prescribed for angina, certain arrhythmias, and rate control, where its predictable slowing of the heart is an asset. Its standing for uncomplicated high blood pressure has been revised honestly in light of evidence suggesting it may lower blood pressure without reducing stroke and mortality as much as some alternatives. That nuanced record makes it a drug clinicians still value in the right context while reserving other agents for first-line hypertension.